Efficacy and safety of glecaprevir/pibrentasvir combination tablets for patients infected with pan-genotypic hepatitis C virus

Efficacy and safety of glecaprevir/pibrentasvir combination tablets for patients infected with pan-genotypic hepatitis C virus - Glecaprevir/pibrentasvir therapy for patients with HCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029652

Enrollment

Registered

2017-11-01

Start date

2017-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients infected with HCV

Exclusion criteria

Exclusion criteria: 1) Patients who do not have consent to clinical research 2) Patietns accompanying HCC 2) Patients with pregnancy

Design outcomes

Primary

Measure	Time frame
Rates of Sustained virological response at 12 and 24 weeks after the end of treatment	—

Countries

Japan

Contacts

Public ContactYoshihito Uchida

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp049-276-1198

Outcome results